INTELLIGENT BIO SOLUTIONS INC.
No enriched coverage for $INBS in the last 7 days.
No SEC Form 4 filings for $INBS in the last 30 days.
Intelligent Bio Solutions (INBS) announced it has regained compliance with Nasdaq's minimum bid price requirement as of January 7, 2026. This follows its common stock trading below $1.00 for 30 consecutive business days, leading to a deficiency notice in December 2025. The company maintained a closing bid price of at least $1.00 for 14 consecutive business days, removing the immediate delisting risk.
Intelligent Bio Solutions (INBS) has announced a strategic manufacturing partnership with Syrma Johari MedTech to scale production of its Intelligent Fingerprinting Drug Screening Reader. This collaboration aims to meet anticipated global demand, support INBS's entry into the US market in 2026, and is expected to achieve over 40% in annual production cost savings while strengthening its supply chain. The partnership leverages Syrma Johari's extensive manufacturing capacity and expertise in medical device production.
Intelligent Bio Solutions (INBS) announced a strategic manufacturing partnership with Syrma Johari MedTech, aiming to reduce production costs by over 40% and improve gross margins by approximately 20 percentage points. This collaboration quadruples manufacturing capacity in preparation for the planned 2026 U.S. market entry of their fingerprint drug screening reader. The partnership leverages Syrma Johari's extensive global facilities and regulatory certifications to strengthen INBS's supply chain and support future growth.
